ILC Therapeutics

ILC Therapeutics Announces Successful Completion of £3.5m Funding Round

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, ILC Therapeutics, Eos, Scottish Enterprise, ILC THERAPEUTICS, EOS, SCOTTISH ENTERPRISE

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.

Key Points: 
  • ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.
  • Chairman Peter Bains said: We are very pleased to complete this important funding round and to strengthen the Board with the appointment of Robert Kopple, Professor David Harrison and Chris Brinsmead.
  • ILC Therapeutics Ltd is an emerging biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates.
  • For more information on ILC Therapeutics, please visit: www.ilctherapeutics.com
    Follow ILC Therapeutics on LinkedIn: www.linkedin.com/company/ilctherapeutics/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005255/en/

UK Biotech Company ILC Therapeutics Announces First International Investment

Retrieved on: 
Tuesday, December 1, 2020
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Infectious diseases, Professional services, ILC Therapeutics, Medical Incubator Japan

UK-based biotechnology company ILC Therapeutics (ILCT) today announced that it has secured significant investment from its first global investor Medical Incubator Japan (MIJ).

Key Points: 
  • UK-based biotechnology company ILC Therapeutics (ILCT) today announced that it has secured significant investment from its first global investor Medical Incubator Japan (MIJ).
  • The Scottish life sciences company, which has received international attention through its work exploring COVID-19 therapeutic treatments with the University of St Andrews, is MIJs first investment in a biotech company in Europe.
  • MIJ President Jun Katsura said: We are delighted that ILC Therapeutics is the first investment of our second fund and our first investment in the UK.
  • For more information on ILC Therapeutics, please visit: www.ilctherapeutics.com
    Follow ILC Therapeutics on LinkedIn: www.linkedin.com/company/ilctherapeutics/
    Medical Incubator Japan K.K is an independent investment firm based in Tokyo specialising in healthcare by a group of healthcare business and investment professionals.